Investment Rating - The investment rating for the company is "Outperform" (Maintain) [1][3] Core Insights - The company reported a revenue of 1.032 billion yuan for 2025, a year-on-year decrease of 16.72%, and a net profit attributable to shareholders of 195 million yuan, down 7.68% year-on-year [3] - The company has adjusted its 2025 profit forecast but maintains its profit projections for 2026 and 2027, expecting net profits of 195 million (originally 201 million), 269 million, and 350 million yuan respectively, with corresponding EPS of 1.44, 1.98, and 2.58 yuan [3] - The company is optimistic about the recovery in the downstream organic silicon and pesticide industries, as well as the delivery of electronic-grade hydroxylamine salt water solution products [3] Financial Summary - The company achieved a revenue of 1.115 billion yuan in 2023, with a projected increase to 1.339 billion yuan in 2026 and 1.616 billion yuan in 2027, reflecting a year-on-year growth of 29.7% and 20.7% respectively [7] - The gross profit margin is expected to improve from 29.6% in 2025 to 30.8% in 2026 and 32.5% in 2027 [10] - The net profit margin is projected to increase from 18.9% in 2025 to 20.1% in 2026 and 21.7% in 2027 [10] Industry Position - The company is a leader in the niche market of silane crosslinking agents and hydroxylamine salts, focusing on the research, production, and sales of ketoxime series fine chemicals [4] - It has established a green circular industrial chain with a strong competitive advantage, supported by a robust intellectual property system with multiple authorized patents [4] - The successful delivery of electronic-grade hydroxylamine water solution to chip manufacturers marks a significant milestone, as this product has high purity requirements and is critical for chip manufacturing processes [5]

Core Viewpoint - The stock of Shandong Boyuan Pharmaceutical Chemical Co., Ltd. experienced a decline of 2.10% on January 19, with a trading volume of 160 million yuan, indicating a potential concern regarding investor sentiment and market performance [1]. Financing Summary - On January 19, Boyuan received a financing buy-in amounting to 16.84 million yuan, while the financing repayment was 18.71 million yuan, resulting in a net financing outflow of 1.86 million yuan [1]. - As of January 19, the total financing and securities lending balance for Boyuan was 155 million yuan, with the financing balance accounting for 3.41% of the circulating market value, which is above the 70th percentile of the past year, indicating a relatively high level [1]. - In terms of securities lending, there were no shares repaid or sold on January 19, with the securities lending balance also at zero, placing it in the 90th percentile of the past year, suggesting a high level of inactivity in this area [1]. Company Overview - Boyuan, established on August 6, 2008, is located in Shouguang City, Shandong Province, and specializes in the research, production, and sales of fine chemicals, including organic and inorganic iodides, precious metal catalysts, and luminescent materials [2]. - The company's revenue composition includes iodides (74.56%), specialty functional chemicals (12.79%), trading business (9.94%), and others (2.72%) [2]. - For the period from January to September 2025, Boyuan reported a revenue of 1.073 billion yuan, reflecting a year-on-year growth of 6.60%, while the net profit attributable to shareholders decreased by 22.53% to 132 million yuan [2]. Shareholder Information - As of January 9, 2025, Boyuan had 8,920 shareholders, a decrease of 5.03% from the previous period, with an average of 5,946 circulating shares per person, which is an increase of 5.29% [2]. - The company has distributed a total of 88.41 million yuan in dividends since its A-share listing [3]. - Notable new institutional shareholders include China Aviation New Start Flexible Allocation Mixed A, holding 1.3456 million shares, and Hong Kong Central Clearing Limited, holding 964,400 shares, among others [3].